Health care provider– and patient-reported outcomes for bictegravir/emtricitabine/tenofovir alafenamide versus other antiretroviral regimens: an observational survey in the United States (July 2021–March 2022)
Positive HCP- and PWH-reported outcomes were seen across ART regimens. However, differences observed, including HCP-reported treatment satisfaction and PWH-reported QoL, favored B/F/TAF compared with other STRs/LAI. Findings support continued use of B/F/TAF for HIV treatment in the United States.
Authors
- Fritha Hennessy (ORCID: https://orcid.org/0000-0002-3387-5423)
- Tim Holbrook
- Woodie Zachry
- Seojin Park
- Joshua Gruber
- Amy E. Colson
- Megan Chen
Institutions
- Adelphi Group (United Kingdom) (GB)
- Gilead Sciences (United States) (US)
- Community Research Initiative (US)
Publication Details
- Journal
- Current Medical Research and Opinion
- Published
- 2025-06-17
- DOI
- https://doi.org/10.1080/03007995.2025.2517692
- Citations
- 4
- Primary Topic
- HIV/AIDS drug development and treatment
- Type
- article
- Field-Weighted Citation Impact
- 5.58